PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Other EventsItem 8.01 Other Events.
As previously reported by PhaseRx, Inc. (the “Company”), to bidding procedures approved by the U.S. Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), bids for substantially all of the Company’s assets were due on Monday, January 22, 2018.
On January 24, 2018, an auction for substantially all of the assets of the Company was held as scheduled but did not conclude. The auction remains open and will be re-scheduled for a date and time to be determined. The hearing scheduled to be held on January 26, 2018, to approve the winning bidder by the Bankruptcy Court and the sale of substantially all of the Company’s assets will also be re-scheduled for a date and time to be determined.
About PhaseRx, Inc. (NASDAQ:PZRX)
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.
